ASCO

AnnualMeeting2016

My videos
Predictive and Prognostic biomarkers for Brain Metastasis
00:00:58

Predictive and Prognostic biomarkers for Brain Metastasis
749 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ANG1005 side effect profile
00:00:37

ANG1005 side effect profile
598 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
ANG1005 shows promise in Brain Cancer
00:01:10

ANG1005 shows promise in Brain Cancer
619 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Blood Brain Barrier and TKI in Brain Cancer treatment
00:01:07

Blood Brain Barrier and TKI in Brain Cancer treatment
712 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treating Brain Metastasis is being redefined due to genomic profiling
00:01:29

Treating Brain Metastasis is being redefined due to genomic profiling
930 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
PD-L1 and Triple Negative Breast Cancer
00:00:42

PD-L1 and Triple Negative Breast Cancer
633 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Current and future Immunotherapy outlook in breast cancer from Annual Meeting 2016
00:01:57

Current and future Immunotherapy outlook in breast cancer from Annual Meeting 2016
870 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
PALOMA trials summary and Palbociclib in ER-positive breast cancer
00:05:15

PALOMA trials summary and Palbociclib in ER-positive breast cancer
640 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Important to biopsy a growing lesion in lung cancer
00:00:36

Important to biopsy a growing lesion in lung cancer
340 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Some patients saw dramatic improvement in IMvigor 210 trial
00:00:43

Some patients saw dramatic improvement in IMvigor 210 trial
406 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
00:00:49

Are safety and adverse event profile appears similar between early trials in both Anti PD-1 and Anti PD-L1
222 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting 2016 update on Small Cell Lung Cancer agents
00:00:59

Annual Meeting 2016 update on Small Cell Lung Cancer agents
456 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
00:01:34

Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
215 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
IMvigor210 response rate durability of response and stable disease
00:01:24

IMvigor210 response rate durability of response and stable disease
266 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
POPLAR trial endpoints median duration of response overall survival and the impact of PD-L1 expression
00:01:04

POPLAR trial endpoints median duration of response overall survival and the impact of PD-L1 expression
261 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Second line treatment of NSCLC patients before immuno-oncology
00:02:05

Second line treatment of NSCLC patients before immuno-oncology
589 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
All comers are eligible in second line urothelial cancer with Atezolizumab
00:01:14

All comers are eligible in second line urothelial cancer with Atezolizumab
467 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Annual Meeting 2016 update on MET in NSCLC
00:01:10

Annual Meeting 2016 update on MET in NSCLC
444 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Some patients saw dramatic improvement in IMvigor 210 trial
00:00:43

Some patients saw dramatic improvement in IMvigor 210 trial
431 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
POPLAR trial success leads to larger OAK study
00:00:28

POPLAR trial success leads to larger OAK study
609 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Autoimmune can be delayed in immunotherapy
00:00:31

Autoimmune can be delayed in immunotherapy
533 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
00:00:30

Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
519 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients
00:03:52

Nivolumab and Pembrolizumab experience in the second line therapy of your NSCLC patients
873 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Phase III NEMO trial and the novel MEK inhibitor Binimetinib
00:01:11

Phase III NEMO trial and the novel MEK inhibitor Binimetinib
911 Views
3 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login